Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?
about
The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.A novel strain of cynomolgus macaque cytomegalovirus: implications for host-virus co-evolutionIdentification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.Study of viral pathogenesis in humanized miceVaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection agaPreventing Congenital Cytomegalovirus Infection: Protection to a 'T'.Repair of a Mutation Disrupting the Guinea Pig Cytomegalovirus Pentameric Complex Acquired during Fibroblast Passage Restores Pathogenesis in Immune-Suppressed Guinea Pigs and in the Context of Congenital Infection.Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.Epigenetic regulation of human cytomegalovirus latency: an update.Xenotransplantation and porcine cytomegalovirus.Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector.Chemokines encoded by herpesviruses.Congenital hearing loss.Antibody Cross-Reactivity between Porcine Cytomegalovirus (PCMV) and Human Herpesvirus-6 (HHV-6).Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.
P2860
Q27692570-395014D3-7232-4D2D-8B7A-C3538646F419Q28601275-BD5E04BF-833A-495F-93DC-DB0D361140ABQ34992770-A2DE23AD-1F6C-42B6-A7CF-53CD21F7BD69Q35685210-F5AFFC22-43AE-4AA0-94BA-3D3B5978A5EAQ36080805-1B65417F-104A-4D8C-B5D3-64556DAEF54DQ36633558-0509B4FC-955B-40D5-A758-7478A3A2731EQ36812617-D7482657-A965-4CEB-BECA-B28BFAB64288Q37182699-55CE6919-8E6A-441A-ABEF-EF95AB9A371FQ37563632-46C63114-8FC3-41F0-B45C-12C73F6B0000Q38272313-A74B0980-5015-44F7-B447-562D0D0C353FQ38588603-58959750-65B1-42A8-9F89-BB50AA68F8D4Q38703382-F5FB1EFA-1B0A-4E5B-BCF4-41FE62150262Q40067378-A9B7A7F7-74F1-46F8-8F40-0EAE593ECE9FQ44259602-09FB1E1B-AB48-4487-94C8-4F52C723AD28Q47133504-8C869531-B394-42B8-8AA5-338193EBC464Q47546281-5140A232-1AE6-4E16-BD59-0C7FFA8CFE3F
P2860
Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Developing a Vaccine against C ...... dels? Where Should We Go Next?
@en
Developing a Vaccine against Congenital Cytomegalovirus
@nl
type
label
Developing a Vaccine against C ...... dels? Where Should We Go Next?
@en
Developing a Vaccine against Congenital Cytomegalovirus
@nl
prefLabel
Developing a Vaccine against C ...... dels? Where Should We Go Next?
@en
Developing a Vaccine against Congenital Cytomegalovirus
@nl
P2860
P356
P1433
P1476
Developing a Vaccine against C ...... dels? Where Should We Go Next?
@en
P2093
Mark R Schleiss
P2860
P304
P356
10.2217/FVL.13.106
P577
2013-12-01T00:00:00Z